Pharmaceutical Microfiltration Market

The pharmaceutical microfiltration market is expected to reach USD 9.94 billion by 2030 from USD 6.13 billion in 2025, at a CAGR of 10.1% between 2025 and 2030. The growth of the pharmaceutical microfiltration market is driven by several key factors, including the increasing adoption of presterilized, gamma-stable microfilters and the expansion of microbial fermentation capacity.

The key players in the pharmaceutical microfiltration industry include Merck KGaA (Germany), Danaher Corporation (US), Sartorius AG (Germany), Parker-Hannifin Corporation (US), Eaton Corporation Plc (Ireland), Thermo Fisher Scientific, Inc. (US), Solventum (US), Donaldson Company, Inc. (US), Porvair Plc (UK), and Alfa Laval Corporate AB (Sweden), among others. Companies in this space are adopting expansion strategies to strengthen their global footprint and advance their technology portfolios. In October 2024, Sartorius introduced the Sartoflow 1000 single-use TFF system, enabling efficient microfiltration and ultrafiltration for clinical-scale biologics with reduced cleaning and faster batch changeovers.

To know about the assumptions considered for the study download the pdf brochure

Merck KGaA (Germany)

Merck's Life Science business offers a comprehensive range of sterilizing-grade filters, tangential-flow filtration cassettes, and virus filters that support aseptic processing, vaccine manufacturing, and advanced biologics, including monoclonal antibodies and cell & gene therapies. The company is strengthening this position with a new climate-neutral USD 150 million filtration manufacturing facility in Blarney, Ireland, scheduled to commence production in late 2025. The facility will focus on devices for aseptic processing, tangential-flow filtration, and virus filtration, thereby enhancing the global security of supply for high-value filter consumables.

Danaher Corporation (US)

Danaher has established itself as a key player in the pharmaceutical microfiltration market, primarily through its renowned bioprocessing brands, Cytiva and Pall. The company offers advanced products, including filtration membranes, depth filters, and fully integrated single-use systems, which are essential for the production of biologics, vaccines, and cell therapies. Danaher focuses on process reliability, contamination control, and scalability, enabling manufacturers to achieve consistent and high-quality results. The company is also making ongoing investments to expand its global manufacturing capacity, particularly by increasing the size of its filtration facilities. These efforts are aimed at meeting the growing demand for high-throughput, end-to-end filtration solutions in next-generation biomanufacturing.

Sartorius (Germany)

Sartorius focuses on integrated single-use filtration solutions, offering sterile filters, membrane cartridges, and pre-configured single-use filter transfer assemblies that are qualified, sterile, and designed to meet EU GMP Annex 1 PUPSIT requirements for final filling, helping customers standardize operations and reduce operator error. Its membrane portfolio spans PES and other polymeric filter types optimized for high flow, low protein binding, and robust microbial retention, supporting critical steps from buffer and media preparation to sterile filtration of biologics and vaccines.

Market Ranking

The pharmaceutical microfiltration market is characterized by significant consolidation. These major companies reinforce their positions through strategic acquisitions, advanced manufacturing capabilities, and extensive distribution networks. Merck KGaA (Germany) offers an extensive Emprove-qualified microfiltration portfolio, including sterilizing-grade membrane cartridges, bacterial-retentive filters, and single-use microfiltration assemblies that help manufacturers meet stringent sterility and regulatory requirements. Danaher (US), through its Cytiva and Pall brands, offers integrated clarification and microfiltration platforms that range from depth-assisted microfilters to high-flux, sterilizing-grade membranes, designed to support scalable, contamination-free bioprocessing. Solventum (US) enhances its position with novel microfiltration media, sterile barrier filters, and particle-control technologies optimized for aseptic drug production.

Related Reports:

Pharmaceutical Microfiltration Market by type (Membrane filter, Depth filter, Virus filter, Air Filter, Assemblies), Sterility Type (Sterile), Application (API, Protein), Scale, End User - Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com